# OnCo record capivasertib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/capivasertib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "capivasertib" ;
  schema:name "Capivasertib"@en ;
  schema:description "Capivasertib (Truqap) is the first AKT inhibitor, for breast cancer with PI3K-pathway mutations and, since 2026, for prostate cancer with PTEN loss."@en ;
  schema:url <https://onco.cc/drugs/capivasertib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Capivasertib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27074756> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Capivasertib>, <https://doi.org/10.1016/j.annonc.2025.12.012> ;
  onco:status "approved" ;
  onco:modality "Small-molecule AKT inhibitor" ;
  schema:alternateName "Truqap" ;
  onco:approval "US 2023: HR+/HER2- breast cancer with PIK3CA/AKT1/PTEN alteration, with fulvestrant", "US 2026: PTEN-deficient metastatic prostate cancer with abiraterone", "EU 2024: ER+/HER2- mBC with PIK3CA/AKT1/PTEN alteration; 17 Jun 2024" ;
  onco:related <https://onco.cc/biomarkers/er-status/>, <https://onco.cc/biomarkers/pik3ca-hotspot-mutation/>, <https://onco.cc/biomarkers/akt1-e17k/>, <https://onco.cc/biomarkers/pten-alteration/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mhspc/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:targets <https://onco.cc/targets/akt/>, <https://onco.cc/targets/pik3ca/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/nct05348577/>, <https://onco.cc/trials/nct07287917/>, <https://onco.cc/trials/nct06635447/>, <https://onco.cc/trials/nct05563220/>, <https://onco.cc/trials/nct04862663/>, <https://onco.cc/trials/nct03742102/>, <https://onco.cc/trials/nct06764186/>, <https://onco.cc/trials/nct03997123/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-schmid-pakt-capivasertib-tnbc-jco-2020/> .